AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms ADMIRE-ICD
- Sponsors GE Healthcare
- 04 Oct 2017 Planned End Date changed from 1 Aug 2019 to 1 Aug 2021.
- 04 Oct 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Aug 2021.
- 28 Jan 2016 New trial record